# An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. Anthracis

> **NCT03088111** · PHASE4 · UNKNOWN · sponsor: **Elusys Therapeutics** · enrollment: 100 (estimated)

## Conditions studied

- Infection, Bacterial
- Anthrax

## Interventions

- **OTHER:** Collection of samples
- **BIOLOGICAL:** Obiltoxaximab

## Key facts

- **NCT ID:** NCT03088111
- **Lead sponsor:** Elusys Therapeutics
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12
- **Primary completion:** 2023-12
- **Final completion:** 2025-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-07-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03088111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03088111, "An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. Anthracis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03088111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*